FDA Approves Wegovy to Lower Risk for CVD Events in Patients With Obesity
FRIDAY, March 8, 2024 -- The U.S. Food and Drug Administration has approved Wegovy (semaglutide) for the prevention of myocardial infarction, stroke, and cardiovascular death in patients with obesity or overweight.
In one multinational study...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Eating Disorders & Weight Management | Food and Drug Administration (FDA) | Heart | Heart Attack | Obesity | Pharmaceuticals | Stroke | Study